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2Guidelines
he  management  of  lung  cancer  is  undergoing
igniﬁcant transition  toward  more  personalized
herapy that  takes  into  account  the  histological
eatures and  molecular  markers  of  the  tumor  in
ddition  to  clinical  features  such  as  smoking  history,
erformance  status  and  comorbidities.
The 2012  Saudi  Lung  Cancer  Guidelines  incorpo-
ated emerging  recommendations  that  have  strong
vidence  and  impact  patient  outcome.
In this  manuscript,  we  will  highlight  the  major
pdates from  the  prior  guidelines.
nitial patient’s assessment
he  initial  patient  assessment  is  critical  to  deter-
ine and  document  3  major  variables,  in  addition
o obtaining  good  history  and  perform  physical
xamination. These  variables  are  performance  sta-
us (PS),  smoking  history  and  comorbidities.
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ttp://dx.doi.org/10.1016/j.jiph.2012.09.012. Performance  status:  Historically,  performance
status is  one  of  the  most  reliable  prognostic  fac-
tors in  lung  cancer.  It  dictated  the  management
of the  patients  for  many  years.  Patients  with
poor PS  status  were  usually  excluded  from  clin-
ical trials  and  therefore,  many  of  the  patients
with poor  PS  were  not  offered  any  cancer  ther-
apy especially  systemic  therapy.
With the  development  of  targeted  therapy
with favorable  therapeutic  index,  many  of  these
patients  now  have  an  option  for  treatment
which was  further  enhanced  by  determining
molecular  markers  that  predicts  beneﬁt  from
this therapy  and  therefore,  minimizing  futile
treatment.
. Smoking  history:  Including  previous  and  current
smoking  history  due  to  its  impact  on  patients
outcome and  its  value  in  enriching  selection  of
patients  for  further  molecular  studies  as  non-
smoking  patients  is  likely  to  have  EGFR  mutation
compared to  smokers.
Furthermore,  continuation  of  smoking  will
negatively impact  and  may  interfere  with
some of  the  treatment  agents  and  decrease
its efﬁcacy  such  as  Tyrosine  Kinase  Inhibitors
(TKIs).
 King  Saud  Bin  Abdulaziz  University  for  Health  Sciences.  All  rights  reserved.
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Therefore,  counseling  current  smokers  about
smoking cessation  is  important  in  providing  bet-
ter patient  care.
3.  Comorbidities:  Knowing  concurrent  chronic  or
acute medical  conditions  is  critical  during
patients’ evaluation  as  some  conditions  will  play
a major  role  in  selecting  therapeutic  interven-
tions for  both  local  (surgery  or  radiation)  or
systemic intervention.
For example,  having  serious  lung  or  heart  diseases
may eliminate  surgery  from  the  treatment  menu
even for  early  stage  lung  cancer  or  at  least  prevent
the performance  of  optimal  cancer  surgery.  Fur-
thermore,  certain  acute  infectious  disease  such  as
hepatitis or  tuberculosis  may  raise  concerns  about
immunosuppressant  chemotherapy  at  least  prior  to
an induction  phase  of  infection  therapy.  The  avail-
ability of  targeted  therapy  that  does  not  cause  bone
marrow suppression  provides  an  excellent  practical
option  for  these  patients.
Initial diagnosis and work-up
This  is  the  most  critical  item  related  to  treatment
decision based  on  the  tumor  characteristics  which
is the  second  component  of  personalized  therapy
(the ﬁrst  one  being  patient’s  characteristics).
Obtaining adequate tumor sample
This  is  often  a  limiting  step  in  the  proper  diagnosis
and work-up  of  lung  cancer  patients  with  com-
mon habit  of  obtaining  the  least  possible  diagnostic
specimen  such  as  cytology  from  bronchial  tree  or
pleural effusion  or  small  biopsy  specimen  by  differ-
ent approaches.
This  approach  once  accepted  as  standard  of
care, is  no  longer  appropriate  for  the  management
of NSCLC  for  the  following  reasons:
1. The  need  to  have  adequate  tissue  to  deter-
mine the  histological  subtype  of  NSCLC  as  this
determination  will  have  major  implication  on
treatment  selection  as  follows:
a. The  documented  beneﬁt  of  certain  treatment
options is  limited  to  histological  subtypes
such as  pemetrexed  and  bevacizumab  in  non
squamous cell  lung  cancer.
b. The  increased  risk  of  complications  such  as
hemorrhage in  squamous  cell  lung  cancer
with bevacizumab.
c. The  decision  of  doing  further  testing  such  as
EGFR mutation  is  generally  recommended  to
non squamous  cell  lung  cancer  histology.
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.  Having  adequate  tissue  is  necessary  to  do  further
testing  besides  immunohistology  (IHC)  such  as
molecular  studies  for  EGFR  mutation  or  EML4-
ALK fusion  tests.
Determining  EGFR  mutation  status  is  an
important factor  in  the  decision  about  proper
utilization of  these  agents  in  the  management
of lung  cancer  especially  the  ﬁrst  line  therapy.
These reasons  highlight  the  importance  of
proper management  of  lung  cancer  specimen  to
make sure  the  specimen  is  utilized  properly  to
have the  best  yield.
taging
he  staging  work-up  by  imaging  studies  was  orga-
ized in  a way  that  is  more  practical  to  avoid
oing tests  that  do  not  impact  patient  manage-
ent. For  example,  the  use  of  PET—CT  Scan  was
imited to  clinical  scenarios  where  curative  treat-
ent is  indicated  to  eliminate  futile  treatment  of
etastatic  disease.  PET  Scan  should  not  be  done
hen it  does  not  have  an  added  value  such  as  in
eﬁnite metastatic  setting.
This is  a practical  approach  due  to  the  shortage
f PET—CT  Scans  in  our  regions.  If  PET  is  not  avail-
ble, then  a  bone  scan  should  be  done  for  stages
B—IV.
isease management
anagement of stages I—III
here  was  no  modiﬁcation  of  the  treatment  of
tages I—III  as  no  new  practice  changing  evidence
merged recently  except  the  impact  of  the  new
taging  system.  For  example,  malignant  pleural
ffusion  became  stage  IVA  and  not  IIIB.
anagement of stage IV
he  management  of  stage  IV  evolved  drastically
ver the  last  couple  of  years.  The  major  changes
ere due  to  incorporation  of  EGFR  mutation  test-
ng and  EML4-ALK  fusion  into  the  practice  and  the
mphasis on  clarifying  the  histological  subtypes
hich has  practical  implication  as  mentioned  ear-
ier.
The treatment  decision  is  based  on  multiple  fac-
ors that  are  summarized  as  following:. Determining  curable  conditions:  such  as  single
brain  or  adrenal  lesion  to  provide  potentially
curable treatment.
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.  Addressing  scenarios  that  require  a  special
attention upfront  such  as  brain  lesion  and
metastatic bone  disease.
. Determining  EGFR  mutation  status  to  initiate  TKI
as early  as  possible  whether  as  ﬁrst  line  (strongly
recommended)  or  switch  maintenance  or  second
line.
The  most  important  message  here  is  that
patients with  EGFR  mutation  should  get  TKIs
irrespective  of  setting  or  performance  status.
Also determining  ALK  fusion  is  important  to  uti-
lize crizotinib  as  early  as  possible.
. Selecting chemotherapy  regimen  based  on  his-
tological  subtypes  favoring  pemetrexed  (over
Gemcitabine)  and  bevacizumab  combinations
for non-squamous  histological  subtypes  doc-
etaxel/paclitaxel  combination  remains  accept-
able option.
. Performance  status  of  the  patient  is  an  impor-
tant determinant  of  the  treatment  selection.
Generally, patients  with  poor  performance  sta-
tus 3—4  are  not  candidate  for  therapy.  However,
patient with  EGFR  mutation  may  be  an  exception
to the  rule  due  to  the  potential  clinical  beneﬁts
and reasonably  safe  toxicity  proﬁle.
ollow-up and surveillance
he  required  tests  were  clariﬁed  based  on  the  clini-
al situation  and  treatment  rendered  conforming  to
he most  common  practice  and  recommendations.
In summary,  2012  Saudi  Lung  Cancer  Guidelines
ncorporated many  recent  advances  in  the  ﬁeld
s personalizing  the  management  of  lung  cancer
ecomes  more  feasible  due  to  major  advances  in
he laboratory  ﬁeld  as  well  as  drug  development.
he manuscripts  in  this  supplement  give  further
etails about  these  issue.
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